Arcutis Biotherapeutics (ARQT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- $0.11
- Estimate
- $0.05
- Surprise
- +120.0%
- Revenue (period 2026-06-30)
- $129.9M
- Score at report (before → after)
- 6.3 → 6.6/10
Revenue source: xbrl.
How the report landed
Arcutis Biotherapeutics (ARQT) beat the $0.05 estimate with adjusted EPS of $0.11 — a large 120.0% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.3/10) to Hold at 6.6/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates ARQT Hold at 6.5/10.
3 of the last 4 quarters beat the estimate; this quarter's +120.0% surprise compares with a +68.8% four-quarter average. Next scheduled report: 2026-10-27.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Strong earnings beat streak (3/4)
What argues against it
- Concentration risk — Product: ZORYVE franchise
- Concentration risk — Supplier: AstraZeneca
- Negative news sentiment (-0.67)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $26.43
- Price target
- $32.19
- Stop
- $24.58
- Upside to target
- +21.8%
- Reward-to-risk
- 1.9:1
The stock trades at 118.6× trailing but 19.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-10-14 — shown for context, not personalized investment advice.
ARQT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.28B
- P/E (fwd)
- 19.2
- P/E (ttm)
- 118.6
- 52-week range
- $19.30–$31.77
- Off 52-week high
- 16.8%
- RSI (14)
- 51
- Volume vs avg
- 0.37×
- Score today
- 6.5/10